MediciNova 
Welcome,         Profile    Billing    Logout  
 4 Products   30 Diseases  4 Products   12 Trials   634 News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eyevinal (ibudilast) / MediciNova
2017-004856-41: Randomised Placebo-controlled Double Blind Clinical Trial in Degenerative Cervical Myelopathy: The RECEDE Myelopathy Trial

Not yet recruiting
3
362
Europe
Ibudilast, N/A, Capsule
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge, NIHR
Degenerative Cervical Myelopathy, ‘Wear and tear’ arthritis (degenerative) affects the part of the spine in the neck (cervical), causing structural changes that compress and damage the spinal cord (myelopathy), Diseases [C] - Nervous System Diseases [C10]
 
 
RECEDE, NCT04631471 / 2017-004856-41: Regeneration in Cervical Degenerative Myelopathy

Recruiting
3
400
Europe
Ibudilast, Cervical decompressive surgery, Matching placebo
Cambridge University Hospitals NHS Foundation Trust, NIHR
Myelopathy, Spinal Cord Diseases
09/26
09/26
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
RECLAIM, NCT05513560: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Active, not recruiting
2/3
460
Canada
Ibudilast, MN-166, Pentoxifylline, Placebo
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
03/25
03/25
ACTRN12619000566134p: OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Not yet recruiting
2
100
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group
Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
 
 
ACTRN12619000566134: OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Recruiting
2
100
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group
Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
 
 
NCT04429555: Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Completed
2
34
US
Ibudilast, MN-166, Placebo
MediciNova
Pneumonia, Viral
06/22
08/24
NCT03594435: Ibudilast for the Treatment of Alcohol Use Disorder

Completed
2
102
US
Ibudilast, Pinatos, MN-166, Placebo oral capsule, Sugar Pill
University of California, Los Angeles, National Institute on Alcohol Abuse and Alcoholism (NIAAA), MediciNova
Alcohol Use Disorder
04/23
04/23
NCT03341078: Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Recruiting
2
120
US
Ibudilast, Placebo Oral Tablet
VA Office of Research and Development, Portland VA Medical Center, Oregon Health and Science University
Methamphetamine-dependence
06/25
12/25
NCT05414240: Ibudilast for Treating Alcohol Use Disorder

Active, not recruiting
2
50
US
Ibudilast, MN-166, previously known as AV411 and the formulation is 10-mg delayed-release Pinatos® capsules, Medical management, Placebo, Inactive substance
University of Pennsylvania
Alcohol Use Disorder (AUD), Alcoholism
12/26
12/27
ACTRN12606000403538: Investigation of AV411 in neuropathic pain

Recruiting
1/2
36
 
Avigen, Inc., Avigen, Inc.
Diabetic neuropathy or Complex regional pain syndrome
 
 
MN-166-GBM-1201, NCT03782415: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Completed
1/2
64
US
MN-166, ibudilast, Temozolomide, TMZ, Temodar, Temodal, Temcad
MediciNova
Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
08/23
08/23
ACTRN12606000410550: Investigation of AV411 in Healthy Subjects

Recruiting
1
16
 
Avigen, Inc., Avigen, Inc.
Healthy subjects
 
 
SEANOBI-ALS, NCT06743776: Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Available
N/A
NA
MN-166
Mayo Clinic, WideTrial, Inc., MediciNova, National Institute of Neurological Disorders and Stroke (NINDS)
ALS
 
 
tipelukast (MN-001) / MediciNova
NCT05464784: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Recruiting
2
40
US
MN-001, MN-001 placebo
MediciNova
Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
12/25
12/26
BC-PIV SARS-CoV-2 vaccine / MediciNova, BioComo
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eyevinal (ibudilast) / MediciNova
2017-004856-41: Randomised Placebo-controlled Double Blind Clinical Trial in Degenerative Cervical Myelopathy: The RECEDE Myelopathy Trial

Not yet recruiting
3
362
Europe
Ibudilast, N/A, Capsule
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge, NIHR
Degenerative Cervical Myelopathy, ‘Wear and tear’ arthritis (degenerative) affects the part of the spine in the neck (cervical), causing structural changes that compress and damage the spinal cord (myelopathy), Diseases [C] - Nervous System Diseases [C10]
 
 
RECEDE, NCT04631471 / 2017-004856-41: Regeneration in Cervical Degenerative Myelopathy

Recruiting
3
400
Europe
Ibudilast, Cervical decompressive surgery, Matching placebo
Cambridge University Hospitals NHS Foundation Trust, NIHR
Myelopathy, Spinal Cord Diseases
09/26
09/26
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
RECLAIM, NCT05513560: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Active, not recruiting
2/3
460
Canada
Ibudilast, MN-166, Pentoxifylline, Placebo
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
03/25
03/25
ACTRN12619000566134p: OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Not yet recruiting
2
100
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group
Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
 
 
ACTRN12619000566134: OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Recruiting
2
100
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group
Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
 
 
NCT04429555: Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Completed
2
34
US
Ibudilast, MN-166, Placebo
MediciNova
Pneumonia, Viral
06/22
08/24
NCT03594435: Ibudilast for the Treatment of Alcohol Use Disorder

Completed
2
102
US
Ibudilast, Pinatos, MN-166, Placebo oral capsule, Sugar Pill
University of California, Los Angeles, National Institute on Alcohol Abuse and Alcoholism (NIAAA), MediciNova
Alcohol Use Disorder
04/23
04/23
NCT03341078: Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Recruiting
2
120
US
Ibudilast, Placebo Oral Tablet
VA Office of Research and Development, Portland VA Medical Center, Oregon Health and Science University
Methamphetamine-dependence
06/25
12/25
NCT05414240: Ibudilast for Treating Alcohol Use Disorder

Active, not recruiting
2
50
US
Ibudilast, MN-166, previously known as AV411 and the formulation is 10-mg delayed-release Pinatos® capsules, Medical management, Placebo, Inactive substance
University of Pennsylvania
Alcohol Use Disorder (AUD), Alcoholism
12/26
12/27
ACTRN12606000403538: Investigation of AV411 in neuropathic pain

Recruiting
1/2
36
 
Avigen, Inc., Avigen, Inc.
Diabetic neuropathy or Complex regional pain syndrome
 
 
MN-166-GBM-1201, NCT03782415: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Completed
1/2
64
US
MN-166, ibudilast, Temozolomide, TMZ, Temodar, Temodal, Temcad
MediciNova
Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
08/23
08/23
ACTRN12606000410550: Investigation of AV411 in Healthy Subjects

Recruiting
1
16
 
Avigen, Inc., Avigen, Inc.
Healthy subjects
 
 
SEANOBI-ALS, NCT06743776: Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Available
N/A
NA
MN-166
Mayo Clinic, WideTrial, Inc., MediciNova, National Institute of Neurological Disorders and Stroke (NINDS)
ALS
 
 
tipelukast (MN-001) / MediciNova
NCT05464784: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Recruiting
2
40
US
MN-001, MN-001 placebo
MediciNova
Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
12/25
12/26
BC-PIV SARS-CoV-2 vaccine / MediciNova, BioComo
No trials found

Download Options